190 related articles for article (PubMed ID: 6112770)
1. Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity.
Usuda S; Nishikori K; Noshiro O; Maeno H
Psychopharmacology (Berl); 1981; 73(2):103-9. PubMed ID: 6112770
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and biochemical studies on a new potential neuroleptic, N-(1-benzyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-08050).
Usuda S; Sano K; Maeno H
Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):68-78. PubMed ID: 43118
[TBL] [Abstract][Full Text] [Related]
3. Dopamine receptors in canine caudate nucleus.
Maeno H
Mol Cell Biochem; 1982 Mar; 43(2):65-80. PubMed ID: 6123940
[TBL] [Abstract][Full Text] [Related]
4. [The inhibition of dopamine D1 and D2 receptors in human putamen by antipsychotic drugs].
Kobayashi T; Shimizu H; Toru M
Yakubutsu Seishin Kodo; 1990 Jun; 10(2):331-4. PubMed ID: 1979198
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and neuroleptic activity of benzamides. Cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide and related compounds.
Iwanami S; Takashima M; Hirata Y; Hasegawa O; Usuda S
J Med Chem; 1981 Oct; 24(10):1224-30. PubMed ID: 6120234
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
7. [Effects of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) on operant avoidance responses in rats (author's transl)].
Kuribara H; Tadokoro S
Nihon Yakurigaku Zasshi; 1981 May; 77(5):521-30. PubMed ID: 7297960
[TBL] [Abstract][Full Text] [Related]
8. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
Fleminger S; Rupniak NM; Hall MD; Jenner P; Marsden CD
Biochem Pharmacol; 1983 Oct; 32(19):2921-7. PubMed ID: 6138043
[TBL] [Abstract][Full Text] [Related]
9. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
Ogren SO; Hall H; Köhler C; Magnusson O; Lindbom LO; Angeby K; Florvall L
Eur J Pharmacol; 1984 Jul; 102(3-4):459-74. PubMed ID: 6149133
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2.
Niznik HB; Grigoriadis DE; Pri-Bar I; Buchman O; Seeman P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jun; 329(4):333-43. PubMed ID: 2863760
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological studies on a new benzamide derivative, YM-09151-2, with potential neuroleptic properties.
Yamamoto M; Usuda S; Tachikawa S; Maeno H
Neuropharmacology; 1982 Oct; 21(10):945-51. PubMed ID: 6128690
[TBL] [Abstract][Full Text] [Related]
12. Potent lipophilic substituted benzamide drugs are not selective D-1 dopamine receptor antagonists in the rat.
Fleminger S; van de Waterbeemd H; Rupniak NM; Reavill C; Testa B; Jenner P; Marsden CD
J Pharm Pharmacol; 1983 Jun; 35(6):363-8. PubMed ID: 6135774
[TBL] [Abstract][Full Text] [Related]
13. Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopaminergic receptors.
Terai M; Usuda S; Kuroiwa I; Noshiro O; Maeno H
Jpn J Pharmacol; 1983 Aug; 33(4):749-55. PubMed ID: 6138453
[TBL] [Abstract][Full Text] [Related]
14. Influence of (-)-sulpiride and YM-09151-2 on stereotyped behavior in chicks and catalepsy in rats.
Wambebe C
Jpn J Pharmacol; 1987 Feb; 43(2):121-8. PubMed ID: 2883335
[TBL] [Abstract][Full Text] [Related]
15. Studies on the mechanism of action of substituted benzamide drugs.
Köhler C; Ogren SO; Fuxe K
Acta Psychiatr Scand Suppl; 1984; 311():125-37. PubMed ID: 6142588
[TBL] [Abstract][Full Text] [Related]
16. Effect of a novel benzamide, YM-09151-2, on rat serum prolactin levels.
Meltzer HY; Mikuni M; Simonovic M; Gudelsky GA
Life Sci; 1983 Feb; 32(9):1015-21. PubMed ID: 6827920
[TBL] [Abstract][Full Text] [Related]
17. The effects of SCH 23390, YM 09151-2, (+)- and (-)-3-PPP and some classical neuroleptics on D-1 and D-2 receptors in rat neostriatum in vitro.
Plantjé JF; Hansen HA; Daus FJ; Stoof JC
Eur J Pharmacol; 1984 Oct; 105(1-2):73-83. PubMed ID: 6208045
[TBL] [Abstract][Full Text] [Related]
18. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
[TBL] [Abstract][Full Text] [Related]
19. Antistereotypic effects of dopamine D-1 and D-2 antagonists after intrastriatal injection in rats. Pharmacological and regional specificity.
Arnt J
Naunyn Schmiedebergs Arch Pharmacol; 1985 Aug; 330(2):97-104. PubMed ID: 2864641
[TBL] [Abstract][Full Text] [Related]
20. Synergistic blockade of some dopamine-mediated behaviours by (-)-sulpiride and SCH 23390 in the rat.
Dall'Olio R; Roncada P; Vaccheri A; Gandolfi O; Montanaro N
Psychopharmacology (Berl); 1989; 98(3):342-6. PubMed ID: 2568655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
